Lantheus (NASDAQ:LNTH) Price Target Lowered to $122.00 at B. Riley

Lantheus (NASDAQ:LNTH) had its price target trimmed by B. Riley from $127.00 to $122.00 in a research note released on Friday,Benzinga reports. The brokerage currently has a buy rating on the medical equipment provider’s stock.

Several other research firms have also recently weighed in on LNTH. The Goldman Sachs Group started coverage on Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price objective on the stock. JMP Securities reiterated a “market outperform” rating and issued a $112.00 price target on shares of Lantheus in a report on Tuesday, January 14th. Truist Financial boosted their price objective on shares of Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, StockNews.com lowered shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $129.43.

Lantheus Price Performance

Lantheus stock opened at $97.71 on Friday. Lantheus has a fifty-two week low of $57.92 and a fifty-two week high of $126.89. The firm has a market capitalization of $6.69 billion, a price-to-earnings ratio of 16.26 and a beta of 0.38. The company’s 50 day simple moving average is $92.67 and its 200 day simple moving average is $96.64.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 EPS for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. As a group, analysts predict that Lantheus will post 6.01 EPS for the current fiscal year.

Insider Transactions at Lantheus

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Mary Anne Heino sold 53,107 shares of the business’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the transaction, the director now owns 440,399 shares in the company, valued at $41,551,645.65. This represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,109 shares of company stock worth $6,110,806 in the last three months. Insiders own 1.50% of the company’s stock.

Institutional Trading of Lantheus

Several institutional investors and hedge funds have recently bought and sold shares of the business. Geode Capital Management LLC increased its holdings in shares of Lantheus by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 1,683,500 shares of the medical equipment provider’s stock worth $184,798,000 after acquiring an additional 32,551 shares during the last quarter. Massachusetts Financial Services Co. MA bought a new position in Lantheus during the third quarter worth $25,955,000. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Lantheus by 47.7% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,684 shares of the medical equipment provider’s stock valued at $1,041,000 after purchasing an additional 3,772 shares during the last quarter. Empirical Asset Management LLC acquired a new position in Lantheus in the 4th quarter valued at about $323,000. Finally, Focus Financial Network Inc. bought a new position in shares of Lantheus during the fourth quarter worth approximately $292,000. Institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.